Topical Rapamycin
Sirolimus (Rapamycin) 0.1% topical cream
A compounded topical sirolimus formulation discussed for skin-aging concerns at a provider's discretion. This off-label use is not FDA-approved.
Legacy treatment library entry
This page is educational. The active Varus flow starts with labs or uploaded results, then moves into clinician review and a care plan before treatment checkout is shown.
What to know
Topical rapamycin uses sirolimus, a drug FDA-approved for other indications, in a compounded cream that may be prescribed off-label for selected patients concerned about skin aging.
Evidence for this use is early. A small Drexel University human study reported changes in certain skin-aging markers and visible skin improvements over months of use, but this is not a large Phase 3 program and results may not be typical.
Compounded topical rapamycin is not FDA-approved, and decisions about whether to prescribe it are made by a licensed provider based on your goals, health history, and tolerance for uncertainty.
How this option is discussed
Rapamycin inhibits mTOR (mechanistic Target of Rapamycin), a protein complex that regulates cell growth, proliferation, and metabolism. In aging skin, overactive mTOR signaling has been associated with:
- Decreased collagen production
- Increased cellular senescence (zombie cells)
- Impaired autophagy (cellular cleanup)
- Chronic low-grade inflammation
Researchers are studying whether local mTOR inhibition in the skin may influence autophagy, senescence markers, and collagen-related pathways. Human evidence remains limited.
Clinical evidence
Small Human Study of Topical Rapamycin for Skin Aging
A small Drexel University study reported increased collagen VII and decreased p16INK4A compared with placebo, alongside visible skin changes over time. The evidence base remains limited and should be interpreted cautiously.
GeroScience (Drexel University) (2019)
Review of mTOR Inhibition and Aging Biology
This review summarizes rapamycin's role in aging biology across preclinical models and provides context for why investigators are studying topical applications. It is not a definitive clinical efficacy study for skin-aging treatment.
Nature Reviews Drug Discovery (2023)
What happens after this library page
Diagnostics-led review
This library entry points into a program, lab review, or upload-labs workflow rather than direct product checkout.
Clinician assessment
A clinician reviews symptoms, medical history, medications, contraindications, and any uploaded or ordered lab results.
Care plan first
Treatment is discussed only after a care plan exists and the next step is clinically clear.
Follow-up and monitoring
Monitoring cadence, refill timing, and additional diagnostics depend on the care plan rather than the public library page.
Frequently asked questions
Off-label use disclosure
- Rapamycin is FDA-approved for other indications; use for skin aging is prescribed off-label at a clinician's discretion.
- The topical formulation described here is compounded and not FDA-approved.
- Human evidence for topical rapamycin in skin aging is limited and includes small studies. Individual results may vary.
Medical services are provided by independent licensed clinicians using the Varus platform. Varus does not provide medical advice, diagnosis, or treatment. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Individual results may vary. This information is for educational purposes and does not constitute medical advice.